Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Gefiitinib as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT04239833 is registered in ClinicalTrials.gov with Nanjing Sanhome Pharmaceutical, Co., Ltd. as lead sponsor.

NCT NCT04239833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04239833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Gefiitinib as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer
Lead sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2020
Completion date
January 31, 2024
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer